Cytiva completed a KUBio installation for Lonza in Guangzhou Biopark, China. The high throughput modular biomanufacturing facility will offer process development and manufacturing for Chinese companies developing innovative medicines, as well as multinationals with manufacturing requirements in China.
The 17,000-square-meter site includes 6,500 square meters of lab space and one KUBio modular facility, and will focus on antibody development services and manufacturing, including for mAbs and other complex proteins.
The Chinese biologics sector’s growth has outpaced global growth, particularly in the last couple of years. According to BioPlan Associates, the biologics market in China has surged from just under $10 billion in 2012 to over $45 billion in 2020.
“With the KUBio and FlexFactory single-use platform now ready for business, Lonza will be able to respond to the great demand for innovative therapies in the current environment, now and in the future,” said Stefan Stoffel, COO, Lonza.
“In a rapidly-growing industry with increasing needs for mAbs and other key biopharmaceuticals, this facility demonstrates the strength of combining modular manufacturing with single-use technologies,” added Olivier Loeillot, vice president, Cytiva. “Together, the KUBio and FlexFactory speed up delivery of innovative therapeutics to patients who need them.”
This is Lonza’s first manufacturing site for biologics in China. Lonza will combine Cytiva’s KUBio modular facility and single-use equipment to support its GMP manufacturing integrated with its own platforms and expertise in development, including cell line construction and process development.
Guangzhou Biopark is also home to manufacturing sites for BeiGene and Akesobio, where Cytiva also provided solutions. Cytiva has delivered 77 KUBio and FlexFactory solutions to customers around the world.
